Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity ...

Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...

Until now, Canada has only had access to vaccine formulas that were approved in fall 2023 and target the Omicron XBB.1.5. Moderna's latest formulation of their mRNA vaccine, Spikevax, targets the KP.2 ...

We apologize, but this video has failed to load. The mRNA vaccine, called Spikevax, has been reformulated to target the KP.2 subvariant of Omicron, the agency said. It replaces the previous ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

As of 11:21 AM EDT. Market Open. Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects ...

On the heels of the nation’s biggest summer COVID surge—test positivity peaked at 17.8% the week ended Aug. 10—help has arrived. The 2024–25 coronavirus vaccines, initially anticipated ...

Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease specialist at $467 million as the craze for biotech IPOs ...

SPIKEVAX ® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season. Moderna will promptly begin ...

Spikevax includes an update to the antigen to combat the latest version of the Omicron variant of the virus. Other vaccines from Pfizer and Novavax are currently being reviewed. Police are asking ...